<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, May 15, 2020 (HealthDay News) — In a stroke population, type 2 diabetes (T2D), but not impaired fasting glucose, is associated with worse cognitive performance, according to a study published online May 14 in Stroke<\/i>.<\/p>\n
Jessica W. Lo, from the University of New South Wales in Sydney, and colleagues examined the impact of impaired fasting glucose and T2D on cognitive performance in a stroke population of 1,601 participants from seven international observational studies. Fasting glucose levels (FGL) during hospitalization were used to define three groups: T2D (FGL \u22657.0 mmol\/L), impaired fasting glucose (6.1 to 6.9 mmol\/L), and normal (<6.1 mmol\/L). Standardized neuropsychological test scores were used to derive domain and global cognition Z scores. The correlations between glucose status and cognitive performance were assessed at three and six months after stroke.<\/p>\n
The researchers found that compared with patients with normal FGL, those with T2D had significantly poorer performance in global cognition (standard deviation [SD], \u22120.59; 95 percent confidence interval, \u22120.82 to \u22120.36; P < 0.001) and in all domains. For patients with impaired fasting glucose and those with normal FGL, no significant difference was seen in global cognition (SD, \u22120.10; 95 percent confidence interval, \u22120.45 to 0.24; P = 0.55) or in any cognitive domain.<\/p>\n
“This emphasizes the importance of interventions to prevent the progression of prediabetes to diabetes mellitus in stroke patients,” the authors write.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n